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Introduction
The advent of gene therapy strategies promises new avenues for the treatment of cancer. A particularly attractive approach is the transfer of so-called suicide genes into tumor cells which, upon expression, can convert pro-drugs into cytotoxic derivates. The herpes simplex virus type 1 (HSV) thymidine kinase (tk) gene has thus far been the most widely studied of such suicide genes. HSVtk has been shown to exert antitumor efficacy in various cancer models both in vitro and in vivo. [1] [2] [3] [4] [5] Expression of the HSVtk gene renders cells susceptible to the antiviral agent ganciclovir (GCV) by converting it into a toxic nucleotide analog which inhibits DNA replication. Cycling cells (eg tumor cells) are effectively killed by such an approach, whereas quiescent cells (eg hepatocytes, neurons) that express tk purportedly are hardly affected. 6 To date, retroviruses have been employed for the transfer of the tk gene into tumor cells. Since successful retroviral infection requires target cells to be replicating, this approach ensured that the tk gene was transferred selectively into actively dividing cells. However, gene transfer either after intratumoral injection of retroviral vector concentrates or after implantation of irradiated vector-virus producing packaging cells has yielded suboptimal trans-duction efficiencies. [7] [8] [9] [10] More recently, vectors derived from human adenoviruses type 2 and 5 have emerged as promising vehicles for in vivo suicide gene transfer. [11] [12] [13] The present study aimed at developing new treatment modalities for unresectable colorectal liver metastases. We tested the efficacy and safety of the HSVtk/GCV combination after in situ transduction of rat colorectal liver metastases, and also evaluated the safety and efficacy of systemic administration, ie intraportal infusion, of adenovirus carrying the HSVtk gene. Our results demonstrate the validity of the approach but reveal that hepatic expression of HSVtk, both in tumor bearing and in tumor-free rats, provokes severe liver dysfunction and mortality upon GCV administration. These data, together with the hepatotropic nature of systemically administered adenovirus type 2-and 5-derived vectors, [14] [15] [16] demonstrate that it will be essential to limit the distribution of the vector to the cells of the tumor. In addition, it will be necessary to monitor liver functions of patients included in gene therapy trials involving adenoviral vectors with the HSVtk gene.
Results
Adenoviral gene transfer into rat and human colorectal tumor cells Adenovirus-mediated gene transfer into rat and human colorectal tumor cells was efficient, exceeding 95% using Ad.CMV␤Gal at a multiplicity of infection (MOI) of 25-100 plaque forming units (p.f.u.). Additionally, rat 452 (CC531) as well as human (LOVO, HT-29, SW837, SW116 and LS180) tumor cells were effectively killed after Ad.CMV.TK transduction and GCV (10 g/ml) treatment (not shown). Exposure of the cultured colorectal tumor cells to adenoviral vectors containing marker genes caused no apparent cytopathogenic effects. Hence, the CC531 cell line can be used as a representative model for colorectal liver metastases in the syngeneic Wag/Rij rat to study the feasibility of suicide gene therapy.
Eradication of thymidine kinase expressing tumors in rat
To evaluate the sensitivity to GCV of tk expressing tumors in vivo, CC531 cells were infected with Ad.CMV.TK, Ad.CMV␤Gal or mock-infected (the latter two groups served as controls). Twenty-four hours after infection, rats (12 per group) were inoculated with the transduced tumor cells (subcapsularly in the liver, 5 × 10 5 cells per site, three sites per rat). In each group six rats were administered GCV (15 mg/kg twice daily intraperitoneally, starting 48 h after operation), the other six received saline as control. During the 18 days of treatment no adverse effects (recovery time after surgery, coat appearance, general activity level or altered survival) were observed, either in the ganciclovir-treated rats or in the controls. No macroscopic or microscopic abnormalities were observed in the liver parenchyma in any of the animals upon death. Rats that had received Ad.CMV␤Gal-transduced tumor cells or nontransduced tumor cells each carried large tumors at the injection sites. In contrast, in the group that had received Ad.CMV.TK-infected CC531 cells, tumors were found only in the saline-treated animals, whereas in GCVtreated animals no tumors had formed (Figure 1 ). These data demonstrate that expression of the HSVtk gene confers sensitivity to GCV in vivo.
Hepatotoxic effects of intraportally injected Ad.CMV.TK and GCV Since intratumoral injection is not a feasible option for the treatment of multiple hepatic metastases in a clinical setting, we tested whether vascular administration of the recombinant adenoviruses would be an efficient route for suicide gene delivery. Rats bearing 6-day-old tumors, were therefore injected intraportally with either 5 × 10 9 p.f.u. Ad.CMV.TK (n = 6), 5 × 10 9 p.f.u. Ad.CMV␤Gal (n = 6) or PBS (n = 3). This dose suffices to infect over 70% of the total number of liver parenchymal cells (not shown). Subsequently, the rats were treated for 18 days, with either GCV or saline. None of the Ad.CMV␤Gal and mock-infected animals showed overt adverse effects upon treatment. In contrast, the rats of the Ad.CMV.TKtreated group that received GCV, but not the saline controls, showed signs of discomfort starting in the first week, eg reduced activity level, unhealthy coat, gazing eyes and weight loss. Consistent with previous experiments, tumors had formed in all rats of the control groups at each of the three injection sites (Figure 2 ). However, no effect of GCV treatment on tumor size was seen in the rats infected with Ad.CMV.TK. Remarkably, the livers of these animals appeared atrophic and yellowish, suggestive of fatty atrophy of the liver. Histological analysis of the livers confirmed major pathology (described in detail in the next paragraph). Serum levels of ASAT, ALAT and bilirubins, 18 days after Ad.CMV.TK transduction, had increased dramatically in the Ad.CMV.TK/GCV-treated animals as compared with the controls (Figure 3 ), confirming severe liver damage.
Toxicity study: intraportal administration of Ad.CMV.TK/GCV in tumor-free rats To clarify the role of the subcapsularly induced liver tumors in the process of the observed liver toxicity, we administered increasing amounts of Ad.CMV.TK intraportally into tumor-free rats. Controls were injected with Ad.CMV␤Gal or PBS (mock). Subsequently, all rats were treated with GCV for 18 days. Weight loss was noticed in the Ad.CMV.TK-infected groups, especially at the two highest titers (Figure 4 ). The condition of the rats that received the highest dose of Ad.CMV.TK deteriorated rapidly and these animals had to be killed 1 week after initiation of GCV treatment. In addition, one of the rats of the medium-dose group of Ad.CMV.TK exhibited similar signs of discomfort. In these tumor-free rats also, serum levels of liver enzymes increased dramatically ( Figure 5 ). Control rats and the other Ad.CMV.TK-treated rats did not show overt signs of discomfort and gained weight, albeit slowly ( Figure 4) . Autopsy of the prematurely killed rats revealed discolored atrophic livers, and atrophic spleens. The rats of the Ad.CMV␤Gal, mock and lowest Ad.CMV.TK group, did not show any macroscopic changes at death.
Figure 4 Weights of rats after intraportal injection with recombinant adenovirus (day 0) followed by 18 days of GCV treatment of all rats
Histological abnormalities after intraportally administered Ad.CMV.TK/GCV Histological pathology was similar in tumor bearing rats and in tumor-free rats. The architecture of the liver was intact and there were no vascular abnormalities. The hepatocytes were large and swollen and showed enlarged nuclei (Figure 6b blasts, reticulocytes, myeloblasts and megakaryocytes) scattered throughout the liver parenchyma indicating extramedullar hematopoiesis (Figure 6b and c) .
A large increase of immune-response cells (T cells, monocytes and macrophages) was seen in the Ad.CMV.TK/GCV-treated group, whereas only a small increase was observed in all other groups receiving adenoviral vectors (Figure 6g-j) (Table 1) .
Additionally, the atrophic spleens of the Ad.CMV.TK/GCV-treated group were severely depleted of lymphoid cells, both T and B cells (Figure 6e and f) , in contrast to the controls (Figure 6d ). Other tissues, as exemplified by the intestine (Figure 6k ), showed no abnormalities.
Discussion
The potential of the suicide gene principle using the HSVtk gene has been described extensively. Currently, phosphorylated GCV is presumed to act via the inhibition of nuclear DNA synthesis during S-phase, 1,6 thus affecting only proliferating cells. In this study, however, we provide evidence that the thymidine kinase and ganciclovir mechanism can interfere not only with proliferating cells, but also with metabolically active, but normally nonproliferating cells.
We initiated the present study to explore the safety and feasibility of new approaches for the treatment of multiple unresectable hepatic metastases. The hepatotropic properties of recombinant adenoviral vectors, inde- pendent of the vascular administration site, can be exploited for in vivo liver-directed gene therapy. 14, 16, 17 First, the proof of principle of the suicide gene approach was confirmed by establishing complete eradication of colorectal tumor cells both in vitro and after ex vivo transduction of CC531 tumors in a rat model. In accordance with the experiments performed by others, [18] [19] [20] we detected no adverse effects of either ex vivo transduction of injected tumor cells or intratumoral administration of adenoviral vectors.
Next, tumor bearing rats were injected systemically, namely into the portal vein, with adenovirus containing the HSVtk gene. Treatment with GCV, however, did not inhibit the growth of the tumor, suggesting that either the virus dose applied was insufficient, or that the peculiar vascularization of the tumor precludes efficient transduction of the tumor cells. 21 More importantly, tk expression in combination with GCV treatment, both in tumor bearing and in nontumor bearing rats, proved to be deleterious for the quiescent and normally nonproliferating hepatocytes, resulting in severe hepatic dysfunction. The observation that upon systemic administration of the HSVtk gene and GCV the tumor growth was enhanced rather than inhibited may be related to this widespread disruption of the tissue structure of the liver parenchyma. Factors that could trigger liver regeneration may also lead to enhanced growth of the tumor.
Microscopic examination of liver sections showed abnormal parenchymal cells and an influx of T cells, macrophages and monocytes, and islands of extramedullar hematopoiesis.
Extramedullar hematopoiesis has been associated with the presence of activated macrophages, which are abundantly present in the livers of tk + GCV-treated animals, creating a favorable microenvionment for hepatic hematopoiesis. 22, 23 The induction of focal hematopoiesis in the adult rat liver has also been claimed to be a secondary effect to severe anemia. 24 Previously, we have shown that vascular delivery of adenoviral vectors, results primarily in transduction of the liver, but also -to a far lesser extent -of the spleen. 25 Therefore, the observed toxicity of the spleen could be due to direct suicide killing of the cycling precursor and stem cells within the hematopoietic reservoir. In this respect it is noteworthy that, although generally lymphocytes are difficult to infect, recent data suggest that the hematopoietic precursor cells of human bone marrow can be efficiently transduced by adenovirus encoding the E. coli ␤-galactosidase gene. 26, 27 Alternatively, it may be a 456 result of effects secondary to the hepatic dysfunction: either via recruitment of large numbers of immune cells from the hematopoietic reservoir to the liver, or via the uptake in the spleen of tk-positive cells (eg macrophages) migrating from the liver. It has been shown by us 25 and by others [14] [15] [16] that over 90% of systemically (or portally) administered adenoviral vectors will home to, and be expressed in, the liver. Consequently, intraportally injected Ad.CMV.TK will primarily transduce the liver, thus rendering the majority of the parenchymal cells tk-positive. Since our data suggest that the combination of the HSVtk gene and GCV is responsible for the liver dysfunction detected in the rats, one could speculate that a minor proliferative stimulus of the liver parenchyma could be responsible for triggering a cascade of destructive events in the liver. The involvement of growing tumor tissue inside the liver parenchyma, inducing some proliferation in the adjacent liver tissue, can be excluded since nontumor bearing rats also show destruction of the liver parenchyma. Two other factors may contribute to the sensitivity of the normally non-mitotic hepatocytes. First, adenovirus injection may trigger some hepatocytes to proliferate. 10 Besides the fact that proliferation in our experiments was only marginally enhanced at death, Brand et al 28 showed significant mortality in mice upon GCV treatment which was started as long as 51 days after Ad.CMV.TK injection, arguing against this hypothesis. Additionally, experiments in adult transgenic mice showing ganciclovir-induced ablation of non-proliferating thyrocytes expressing HSVtk by Wallace et al 29 corroborate our findings. Second, the rapid onset of toxicity and the fact that only few immune cells were found in the liver after injection of adenovirus encoding marker genes argues against an immunological basis of the toxicity.
Alternatively, the toxicity caused by HSVtk and GCV may be brought about not only by interfering with cellular DNA synthesis, but also by inhibition of mitochondrial DNA (mtDNA) synthesis in the parenchymal cells. Hepatocytes are known to be nonproliferating, but metabolically very active cells: one single hepatocyte can harbor up to 2000 mitochondria providing the energy needed for its function. Phosphorylated nucleoside analogs appear to be transported into the mitochondria and to exert their inhibitory effect on mtDNA synthesis. [30] [31] [32] Mitochondria are selective in their membrane permeability, however, it has been shown 33, 34 that other antiviral nucleotide anologues can be efficiently incorporated into mitochondrial DNA and inhibit mtDNA polymerase. 31, 35 In humans multi-system toxicity due to nucleoside analogues, affecting slowly proliferating but metabolically active tissues (liver, pancreas, muscle, neuronal tissue), has been described for zidovudine, didanosine and zalcitabine, fialuridine, stavudine and lamivudine. [36] [37] [38] [39] Recently, a clinical trial using fialuridine for the treatment of hepatitis B viral infection failed due to high liver toxicity attributed to generalized mitochondrial injury, which cost the lives of 13 of the 15 patients treated. 40 In line with such a mechanism, light microscopy of livers of Ad.CMV.TK/GCV-treated rats, showed marked accumulation of macro-and micro-vesicular fat, depletion of glycogen, iron precipitation and scant hepatocellular necrosis and apoptosis. Electron microscopy revealed hypodense matrices and aberrant cristae of the mitochondriae specifically in the AdCMV.TK/GCV-treated group, providing further evidence for mitochondrial defects. Although attractive, this mechanism has yet to be formally confirmed to be involved in the GCV toxicity in Ad.CMV.TK-treated rats.
Implications for the design of clinical gene therapy trials Irrespective of the underlying mechanism, the occurrence of hepatic failure emphasizes the importance of restricting the expression of the HSVtk gene to the tumor. Apart from local administration, such tumor-specific expression could be achieved via several other mechanisms. First, vector binding and entry (in)to the tumor cells could be made specific, for instance by modifying the virus' fiber protein resulting in interaction with surface markers unique for the cells of the tumor. [41] [42] [43] Second, the transcription of the transgene could be restricted to the tumor cells, eg by virtue of tumor-specific promotors. 44, 45 Even with extrahepatic administration, upon systemic leakage, adenoviral vectors will transduce the liver, as has been observed in experimental animal models. 53 Preliminary data of a clinical trial for patients with malignant mesothelioma revealed mild to moderate anemia and transient elevations of liver functions after intrapleural instillment of adenoviral vectors carrying the tk gene followed by GCV treatment. 46 Even though liver and bone marrow functions can, and should, be monitored during the treatment of Ad.CMV.TK-injected patients, and ganciclovir administration can be discontinued at any time, our data might suggest a limitation for clinical application involving adenovirus-mediated transfer of suicide genes.
Materials and methods
Cells and cell culture All cells were maintained in high-glucose Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum at 37°C/5% CO 2 (GIBCO Laboratories, Grand Island, NY, USA). The CC531 cell line is a 1,2-dimethylhydrazine-induced, moderately differentiated adenocarcinoma of the colon, syngeneic with Wag/Rij rats. 47 SW116, SW837, LOVO, HT-29 and LS180 are immortalized human adenocarcinoma cells derived from primary colorectal tumors.
Viruses and virus techniques
Construction of the recombinant adenoviral vectors Ad.CMV␤Gal 48 and Ad.CMV.TK 49 under the control of the cytomegalovirus enhancer/promotor (CMV) have been reported previously. The recombinant virus was propagated on 911 cells 50 and purified by double CsCl density centrifugation. Titers of the viral stocks were determined by plaque assay on 911 cells as described by Fallaux et al. 50 Stocks were routinely checked for the presence of replication-competent adenoviruses (RCA) by infection of HepG2 cells and by polymerase chain reaction (PCR) (van den Wollenberg, unpublished). In the stocks used no RCA could be detected (PCR sensitivity approximately 1 per 5 × 10 7 p.f.u.).
Tumor model
Male Wag/Rij rats (Harlan/CPB, Zeist, The Netherlands), weighing 200-250 g, were used for in vivo 457 experiments. Cultured CC531 cells were harvested by trypsinization and viable cells were counted and diluted in Hank's balanced salt solutions to a concentration of 5 × 10 5 cells/50 l and stored on ice until injection. For tumor cell implantation, a laparotomy was performed and 5 × 10 5 cells were injected subcapsularly in the major three liver lobes using a 0.45-gauge needle. On day 21 after tumor cell injection, established tumors were measured with microcalipers. Tumor sizes were calculated by multiplying maximum tumor length and width. After removal, part of the organs was snap frozen in liquid isobutanol and stored at −80°C, the remainder was fixed in 3.7% formaldehyde.
Gene transfer
For ex vivo gene transfer, cultured CC531 cells were infected with Ad.CMV␤Gal and Ad.CMV.TK at a MOI of 25 and harvested the next day and prepared for subcapsular liver injection as described earlier. For in vivo gene transfer rats were re-opened 6 days after tumor cell injection and 1 ml of virus containing suspension was slowly injected into the portal vein.
Immunohistochemistry
Cryostat sections (5 m) from the liver were fixed in acetone for 5 min and incubated with the first mAb, either ED1, a monoclonal antibody specific for rat macrophage membrane antigen, 51 or R73, an anti-T cell receptor-␣␤-specific monoclonal antibody 52 (1:50; 1:500 respectively) in 10% NRS (normal rat serum) for 60 min. After rinsing with PBS, the sections were incubated with a second rabbit-anti-mouse antibody (1:100) and a third swine-antirabbit peroxidase-conjugated antibody (1:50), both for 30 min. Sections were developed in 3,3-diaminobenzidine (DAB) and counterstained with hematoxylin and mounted in malinol. Paraffin-embedded sections were stained with hematoxylin-eosin (HE), with periodic acid-Schiff (PAS) with and without diastase, or were Fe-stained.
Blood measurements
Blood chemistry measurements were performed by automatic colorimetric assays (Hitachi 747, Boehringer Mannheim, Mannheim, Germany).
Statistics P values were calculated with the Student's t test.
